TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07621237: A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Sponsor: Tonix Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT07621237 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07621237 Rescue Dossier →